benfluorex (S 780)

RN given refers to parent cpd without isomeric designation; structure

Also Known As:

S 780; 1-(2-trifluoromethylphenyl)-2-(benzoyloxyethyl)aminopropane HCl; 780 SE; JP 992; SE 780; benfluorex hydrochloride; benfluorex hydrochloride, (+-)-isomer; benfluorex maleate; benfluorex, methanesulfonate salt; benfluramate; N-(2-benzoyloxyethyl)norfenfluramine

Networked: 92 relevant articles (11 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Ethylamines: 5
    - Phenethylamines: 28
      - Fenfluramine: 954
        benfluorex: 92

Experts

1.	Tribouilloy, Christophe: 12 articles (12/2015 - 08/2010)
2.	Jobic, Yannick: 11 articles (01/2016 - 04/2010)
3.	Bruneval, Patrick: 9 articles (01/2018 - 03/2012)
4.	Ennezat, Pierre-Vladimir: 9 articles (01/2017 - 12/2012)
5.	Maréchaux, Sylvestre: 9 articles (12/2015 - 04/2011)
6.	Etienne, Yves: 6 articles (01/2016 - 04/2010)
7.	Andréjak, Michel: 6 articles (12/2015 - 08/2010)
8.	Rusinaru, Dan: 6 articles (02/2015 - 08/2010)
9.	Jeu, Antoine: 4 articles (02/2015 - 11/2011)
10.	Frachon, Irène: 4 articles (04/2013 - 04/2010)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 01/01/2012 - "Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus." 06/01/1989 - "In NIDDM patients treated with benfluorex, normalisation of basal blood glucose levels was accompanied by an improvement in the OGTT blood glucose curve which was statistically significant relative to Group B. " 01/01/2012 - "REGULATE trial was designed to compare the efficacy and safety of benfluorex versus pioglitazone in type 2 diabetes mellitus (DM) patients. " 02/01/1998 - "Added benfluorex in obese insulin-requiring type 2 diabetes." 10/01/1996 - "Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo."
2.	Insulin Resistance 01/01/1999 - "It has been reported that benfluorex ameliorates the insulin resistance induced by high-fat feeding when its administration is initiated at the same time as the change in diet. " 11/01/1993 - "It is concluded that in this short-term study benfluorex increases insulin sensitivity in obese type 2 diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)" 03/01/2006 - "Significant between-group differences in favor of benfluorex were observed for mean FPG (-1.65 mmol/l) (P < 0.001) and for homeostasis model assessment of insulin resistance. " 01/01/1999 - "Here we have examined whether benfluorex reverses insulin resistance when this is established in middle-aged rats chronically maintained on a high-fat diet. " 09/01/1996 - "The increase in the insulin sensitivity index (Kitt) was greater with benfluorex (+0.54 +/- 1.4 versus +0.25 +/- 1.3%/mn), but the difference was not statistically significant. "
3.	Obesity 09/01/1977 - "The effects of benfluramate on carbohydrate metabolism in obesity." 09/09/1992 - "These studies confirm that, in an animal model of obesity associated with insulin resistance, benfluorex exerts a marked hypolipidemic effect and improves insulin resistance. " 09/01/1997 - "Adjunct treatments comprise a few pharmacological approaches which may help to improve glycaemic control by correcting some abnormalities frequently associated with NIDDM, such as obesity (serotoninergic anorectic agents) and hyperlipidaemia (benfluorex). " 09/01/1996 - "In type II diabetics with mild obesity and hyperglycemia previously managed with diet alone, benfluorex has significant long-term effect on HbA1c and mean daily blood glucose, and tends to lower insulinemia." 09/01/1996 - "A randomized double-blind study of benfluorex (150 mg x 3 daily) versus placebo was conducted over 3 months in 32 type II diabetic patients (24 men and 8 women, aged 52 +/- 8.4 years) with mild stable obesity [body-mass index (BMI) 27 +/- 1.6 kg/ m2], moderate fasting hyperglycemia (fasting blood glucose 9 +/- 0.5 mmol/L, HbA1c 6.7 +/- 0.9%) and moderate hyperinsulinemia (18.6 +/- 3.0 microU/mL) when on treatment with diet alone. "
4.	Body Weight (Weight, Body) 09/01/1996 - "At the end of the study, the groups did not differ in body weight or BMI; however, HbA1c decreased more with benfluorex (6.0 +/- 1.0% versus 6.8 +/- 0.9%, p = 0.024), as did the mean glycemic profile (7.8 +/- 1.4 versus 8.5 +/- 1.7 mmol/L, p < 0.001), including a particular decrease in postprandial glycemia. " 08/01/1996 - "Pair-fed rats showed body weights virtually identical with those of benfluorex-treated animals. " 08/01/1996 - "Benfluorex at 35-40 mg.kg-1 body weight was administered in the food from 10 to 14 weeks of age and resulted in an initial 50% decrease in food consumption. " 08/20/1991 - "Rats of the JCR:LA-corpulent strain were treated with benfluorex daily at a dose of 25 mg/kg body weight. " 02/01/1998 - "Addition of benfluorex in obese insulin-requiring Type 2 diabetes thus enhances glycaemic control and lowers both daily insulin requirement and body weight. "
5.	Hypertriglyceridemia 02/01/2004 - "(3) Benfluorex is sold in France as an adjunctive treatment for hypertriglyceridemia and diabetes with overweight. " 01/01/1998 - "[Benfluorex (Mediator): non-insulin-dependent diabetes and hypertriglyceridemia]." 09/01/2011 - "As compared with the 'no ASD' group (n= 12), patients in the benfluorex group (n= 34) were more frequently female, had more frequent arterial hypertension and hypertriglyceridemia, and presented more frequently with combined mitral and aortic disease (79 vs. 8%, P < 0.001). " 03/01/2011 - "Benfluorex, an amphetamine derivative, was marketed as an adjunctive drug for patients with hypertriglyceridemia or diabetes with overweight. " 08/20/1991 - "The changes produced by benfluorex are all in directions that should inhibit atherogenesis in this animal model for the human obesity/hypertriglyceridemia/insulin resistant syndrome."

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Blood Glucose (Blood Sugar)
3.	Glucose (Dextrose)
4.	Biguanides
5.	Lipids
6.	Pioglitazone (Actos)
7.	Triglycerides (Triacylglycerol)
8.	Appetite Depressants (Anorectics)
9.	Hypoglycemic Agents (Hypoglycemics)
10.	Lactic Acid (Lactate)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Aftercare (After-Treatment)
4.	Oral Administration
5.	Caloric Restriction